Skip to main content

Advertisement

SpringerLink
Log in

IL-6 and MCP-1 genetic polymorphisms are predictive of decreased platelet counts caused by chemoradiotherapy in esophageal cancer

  • Original Article
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Background

A reliable marker of the sensitivity of esophageal cancer to chemoradiotherapy (CRT) as well as a personal biomarker predictive of adverse events during treatment has long been sought. The purpose of the present study was to test whether there is an association between interleukin-6 (IL-6) and/or monocyte chemoattractant protein-1 (MCP-1) polymorphisms and CRT-induced bone-marrow suppression––i.e., reductions in white blood cell and/or platelet counts.

Methods

The study participants were 103 Japanese patients treated with definitive or pre-operative CRT for squamous cell esophageal cancer at Akita University Hospital. The patients were divided into two groups, with or without adverse events during or up to 1 month after CRT.

Results

Patient backgrounds––i.e., white blood cell and platelet counts before CRT and doses of chemotherapy and irradiation––did not differ between groups. However, there was a significantly higher incidence of grade 2–4 platelet count reductions (<75,000/mm3) among patients carrying the IL-6 −634C/G+G/G genotype than among those carrying the C/C genotype. Similarly, there was a significantly higher incidence of grade 2–4 platelet count reductions among patients carrying the MCP-1 −2518G/G genotype than among those carrying the A/A+A/G genotype. Univariate and multivariate logistic regression models revealed that the IL-6 −634C>G and MCP-1 −2518A>G polymorphisms were significantly associated with grade 2–4 platelet count reductions following CRT.

Conclusion

These polymorphisms may thus be clinically relevant and should be taken into consideration when devising CRT regimens or treatment strategies for esophageal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chen MF, Yang YH, Lai CH, et al. Outcome of patients with esophageal cancer: a nationwide analysis. Ann Surg Oncol. 2013;20:3023–30.

    Article  PubMed  Google Scholar 

  2. Kumagai K, Rouvelas I, Tsai JA, et al. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. Br J Surg. 2014;101:321–38.

    Article  CAS  PubMed  Google Scholar 

  3. Motoyama S, Sugiyama T, Ueno Y, et al. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg Oncol. 2006;13:1724–31.

    Article  PubMed  Google Scholar 

  4. Hayashi K, Motoyama S, Sugiyama T, et al. REG Iα is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients. Ann Surg Oncol. 2008;15:1224–31.

    Article  PubMed  Google Scholar 

  5. Yoshino K, Motoyama S, Koyota S, et al. Identification of insulin-like growth factor 2 mRNA-binding protein 3 as a radioresistance factor in squamous esophageal cancer cells. Dis Esophagus. 2014;27:479–84.

    Article  CAS  PubMed  Google Scholar 

  6. Hayashi K, Motoyama S, Koyota S, et al. REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells. Cancer Sci. 2008;99:2491–5.

    Article  CAS  PubMed  Google Scholar 

  7. Yoshino K, Motoyama S, Koyota S, et al. IGFBP3 and BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun. 2011;404:1070–5.

    Article  CAS  PubMed  Google Scholar 

  8. Sato Y, Motoyama S, Nanjo H, et al. REG1A expression status predicts chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy. Ann Surg Oncol. 2013;20:3044–51.

    Article  PubMed  Google Scholar 

  9. Anthony BA, Link DC. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol. 2014;35:32–7.

    Article  CAS  PubMed  Google Scholar 

  10. Skoog T, van’t Hooft FM, Kallin B, et al. A common functional polymorphism (C–>A substitution at position −863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet. 1999;8:1443–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.

    CAS  PubMed  Google Scholar 

  12. Buraczynska M, Jozwiak L, Ksiazek P, et al. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res. 2007;150:101–5.

    Article  CAS  PubMed  Google Scholar 

  13. Szalai C, Duba J, Prohaszka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 −2518G/G genotype in CAD patients. Atherosclerosis. 2001;158:233–9.

    Article  CAS  PubMed  Google Scholar 

  14. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115:3339–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Burstein SA. Effects of interleukin 6 on megakaryocytes and on canine platelet function. Stem Cells. 1994;12:386–93.

    Article  CAS  PubMed  Google Scholar 

  16. Heits F, Stahl M, Ludwig D, et al. Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease. J Interferon Cytokine Res. 1999;19:757–60.

    Article  CAS  PubMed  Google Scholar 

  17. Walston JD, Fallin MD, Cushman M, et al. IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet. 2007;122:485–94.

    Article  CAS  PubMed  Google Scholar 

  18. Nakajima T, Ota N, Yoshida H, et al. Allelic variants in the interleukin-6 gene and essential hypertension in Japanese women. Genes Immun. 1999;1:115–9.

    Article  CAS  PubMed  Google Scholar 

  19. Kitamura A, Hasegawa G, Obayashi H, et al. Interleukin-6 polymorphism (−634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med. 2002;19:1000–5.

    Article  CAS  PubMed  Google Scholar 

  20. Ryu JH, Kim SJ. Interleukin-6 −634C/G and −174G/C polymorphisms in Korean patients undergoing hemodialysis. Korean J Intern Med. 2012;27:327–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Motoyama S, Nakatsu T, Miura M, et al. Interleukin-6 −634G>C genetic polymorphism associates with prognosis following surgery for advanced thoracic esophageal squamous cell carcinoma. Dig Surg. 2012;29:194–201.

    Article  CAS  PubMed  Google Scholar 

  22. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Takahashi M, Masuyama J, Ikeda U, et al. Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res. 1995;76:750–7.

    Article  CAS  PubMed  Google Scholar 

  24. Milner JD, Orekov T, Ward JM, Cheng L, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood. 2010;116:2476–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA. 1999;282:561–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Akita University Hospital, Akita, Japan

    Kazuma Fujita, Takenori Niioka & Masatomo Miura

  2. Department of Comprehensive Cancer Control, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

    Satoru Motoyama

  3. Department of General Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan

    Satoru Motoyama, Yusuke Sato, Kei Yoshino, Tomohiko Sasaki, Jiajia Liu & Yoshihiro Minamiya

  4. Department of Radiology, Akita University Graduate School of Medicine, Akita, Japan

    Akira Anbai

Authors
  1. Kazuma Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Motoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kei Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomohiko Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiajia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takenori Niioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Anbai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshihiro Minamiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masatomo Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoru Motoyama.

Ethics declarations

Ethical Statement

This study was approved by the institutional review boards of Akita University Graduate School of Medicine (#419). Additional informed consent was obtained from all patients for whom identifying information is included in this article.

Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fujita, K., Motoyama, S., Sato, Y. et al. IL-6 and MCP-1 genetic polymorphisms are predictive of decreased platelet counts caused by chemoradiotherapy in esophageal cancer. Esophagus 13, 264–269 (2016). https://doi.org/10.1007/s10388-016-0522-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-016-0522-z

Keywords

Search

Navigation